BioSpace News Archive

Merus N.V. today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences: Guggenheim 6th Annual Biotechnology Conference: Wednesday, February 7, 2024 at 2:30 p.m. ET.

USGI Medical, Inc., the pioneer of incisionless weight loss procedures and devices, announced that the United States Food and Drug Administration has approved an Investigational Device Exemption application to conduct a pivotal study of its POSE2.0®incisionless procedure for primary obesity.

Kuros Biosciences, a leader in next generation bone graft technologies, announced clearance of a 510 submission from the U.S. Food and Drug Administration related to its MagnetOs ™ Granules.

Bioz, Inc. is excited to announce its partnership with Larodan, a prominent manufacturer of research grade lipids.

Immunovia announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates.

Cencora, Inc. reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced its participation in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, being held February 13-14, 2024 at the Cliff Lodge in Snowbird, Utah.